MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 461074 | Name: R 61837

Description:

WARNING: This product is for research use only, not for human or veterinary use.

R 61837 is an antirhinoviral agent.

Chemical Structure

R 61837
R 61837
CAS#100241-46-1

Theoretical Analysis

MedKoo Cat#: 461074

Name: R 61837

CAS#: 100241-46-1

Chemical Formula: C16H20N4O

Exact Mass: 284.1637

Molecular Weight: 284.36

Elemental Analysis: C, 67.58; H, 7.09; N, 19.70; O, 5.63

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
R 61837; R-61837; R61837;
IUPAC/Chemical Name
3-methoxy-6-(4-(m-tolyl)piperazin-1-yl)pyridazine
InChi Key
DDOAUTHWSCUHQA-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H20N4O/c1-13-4-3-5-14(12-13)19-8-10-20(11-9-19)15-6-7-16(21-2)18-17-15/h3-7,12H,8-11H2,1-2H3
SMILES Code
CC1=CC(N2CCN(C3=NN=C(OC)C=C3)CC2)=CC=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 284.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Andries K, Dewindt B, Snoeks J, Willebrords R, van Eemeren K, Stokbroekx R, Janssen PA. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother. 1992 Jan;36(1):100-7. PubMed PMID: 1317142; PubMed Central PMCID: PMC189235. 2: Chapman MS, Minor I, Rossmann MG, Diana GD, Andries K. Human rhinovirus 14 complexed with antiviral compound R 61837. J Mol Biol. 1991 Feb 5;217(3):455-63. PubMed PMID: 1847215. 3: Andries K, Dewindt B, De Brabander M, Stokbroekx R, Janssen PA. In vitro activity of R 61837, a new antirhinovirus compound. Arch Virol. 1988;101(3-4):155-67. PubMed PMID: 2845889. 4: Dewindt B, van Eemeren K, Andries K. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses. Antiviral Res. 1994 Sep;25(1):67-72. PubMed PMID: 7811059. 5: Moeremans M, De Raeymaeker M, Daneels G, De Brabander M, Aerts F, Janssen C, Andries K. Study of the parameters of binding of R 61837 to human rhinovirus 9 and immunobiochemical evidence of capsid-stabilizing activity of the compound. Antimicrob Agents Chemother. 1992 Feb;36(2):417-24. PubMed PMID: 1318682; PubMed Central PMCID: PMC188450. 6: Andries K, Dewindt B, Snoeks J, Willebrords R. Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization. Arch Virol. 1989;106(1-2):51-61. PubMed PMID: 2548460. 7: Kim KH, Willingmann P, Gong ZX, Kremer MJ, Chapman MS, Minor I, Oliveira MA, Rossmann MG, Andries K, Diana GD, et al. A comparison of the anti-rhinoviral drug binding pocket in HRV14 and HRV1A. J Mol Biol. 1993 Mar 5;230(1):206-27. PubMed PMID: 8383771. 8: Oren DA, Zhang A, Nesvadba H, Rosenwirth B, Arnold E. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14. J Mol Biol. 1996 May 31;259(1):120-34. PubMed PMID: 8648640. 9: Dearden C, al-Nakib W, Andries K, Woestenborghs R, Tyrrell DA. Drug resistant rhinoviruses from the nose of experimentally treated volunteers. Arch Virol. 1989;109(1-2):71-81. PubMed PMID: 2558631. 10: al-Nakib W, Higgins PG, Barrow GI, Tyrrell DA, Andries K, Vanden Bussche G, Taylor N, Janssen PA. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob Agents Chemother. 1989 Apr;33(4):522-5. PubMed PMID: 2543283; PubMed Central PMCID: PMC172472.

View History

AA92593

AA92593

New Featured